Cough News and Research RSS Feed - Cough News and Research

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

FDA grants orphan-drug designation to Genoa's pirfenidone for treatment of IPF disease

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program - inhaled GP-101 for the treatment of IPF. [More]
Preoperative urodynamics ‘has no added value’ in SUI patients

Preoperative urodynamics ‘has no added value’ in SUI patients

Preoperative urodynamic studies may be unnecessary in many women undergoing primary surgery for stress urinary incontinence, say the authors of a systematic review and meta-analysis. [More]
NSAID use may mask early pneumonia symptoms

NSAID use may mask early pneumonia symptoms

People with pneumococcal pneumonia who are taking nonsteroidal anti-inflammatory drugs at the point of diagnosis tend to develop more severe disease despite being younger and healthier than those not using these drugs, shows research. [More]
Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

Chronic obstructive pulmonary disease flare-ups: an interview with Dr. MeiLan Han, University of Michigan and Scott Cerreta, Director of Education, COPD Foundation

During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Computational biologists develop program for easy diagnosis of hereditary illnesses

Computational biologists develop program for easy diagnosis of hereditary illnesses

In the case of a cough or a sore throat, the doctor can usually diagnose a common cold immediately. However, the diagnosis of hereditary illnesses like cystic fibrosis, which affects the metabolism, or Huntington's disease, which leads to cognitive decline, is much more complex. [More]
Doctors remind parents about importance of immunizing children

Doctors remind parents about importance of immunizing children

Doctors at Cincinnati Children's Hospital Medical Center want to remind parents about the importance of immunizing their children when preparing to send the children back to school. [More]
Trials show immunizations are effective in adults

Trials show immunizations are effective in adults

As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert. [More]

Showers and rivers may play role in the development of Crohn's disease

Humans may be exposed to bacteria linked with Crohn's disease through fine spray from showers and rivers according to research led by Lancaster University. [More]
Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Highlights: Florida officials crack down on direct Medicaid marketing; a wellness plan in Washington state breaks the mold

Highlights: Florida officials crack down on direct Medicaid marketing; a wellness plan in Washington state breaks the mold

[Florida] health officials are taking a cue from past problems and are banning health insurance companies from marketing their plans directly to Medicaid consumers as the state is rolling out a massive overhaul by transitioning millions into managed care. Insurance companies are allowed to market to consumers under the contracts, but only if the state gives prior approval (Kennedy, 7/22). [More]
First Edition: July 22, 2014

First Edition: July 22, 2014

Reporting for Kaiser Health News, Susan Jaffe writes: "Medicare officials have allowed patients at dozens of hospitals participating in pilot projects across the country to be exempted from the controversial requirement that limits nursing home coverage to seniors admitted to a hospital for at least three days. [More]
FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). [More]
CVS Caremark enters into definitive agreement to acquire Navarro Discount Pharmacy

CVS Caremark enters into definitive agreement to acquire Navarro Discount Pharmacy

CVS Caremark today announced that it has entered into a definitive agreement to acquire the assets of Miami-based Navarro Discount Pharmacy, the largest Hispanic-owned drugstore chain in the U.S. The transaction includes Navarro's 33 retail drugstore locations and Navarro Health Services, a specialty pharmacy serving patients with complex or chronic diseases. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
Perrigo receives final approval from FDA for congestion relief tablets

Perrigo receives final approval from FDA for congestion relief tablets

Perrigo Company today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil Congestion Relief Tablets, 200 mg/10 mg. [More]
RD Biomed announces Chinese distribution agreement for reflux diagnostic tool Peptest

RD Biomed announces Chinese distribution agreement for reflux diagnostic tool Peptest

RD Biomed, the Yorkshire medical technology company, has announced a Chinese distribution agreement for its world-leading reflux diagnostic tool Peptest. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]